Eli Lilly and Company
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Eli Lilly and Company
Public Company Edition: Arvinas grossed $350m in a private placement, while Xenon brought in $345m and Pharvaris raised $300m in follow-on public offerings. Fundraising remains challenging, however, so IGM Biosciences, Hansa Biopharma and other companies cut costs to save money.
Investors balked at Sanofi plans to raise R&D spending and eat into profits, so CEO Paul Hudson and new R&D chief Houman Ashrafian need to convince doubters that its immunology focused plan will pay off.
ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
- Other Names / Subsidiaries
- Akouos, Inc.
- Alnara Pharmaceuticals, Inc.
- ARMO BioSciences, Inc.
- Applied Molecular Evolution
- Avid Radiopharmaceuticals, Inc.
- Bowfin Acquisition Corporation
- Class AP
- CoLucid Pharmaceuticals, Inc.
- Dermira Inc.
- Disarm Therapeutics, Inc.
- ICOS Corporation
- ImClone Systems
- Loxo Oncology, Inc. (LOXO)
- Protomer Technologies
- SGX Pharmaceuticals (Structural GenomiX)
- Valocor Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.